Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City. The company plans to host one-on-one meetings and deliver a presentation, which will also be available virtually through their website, https://kairospharma.com.
This participation is significant as it provides Kairos Pharma with a platform to showcase its innovative approach to overcoming drug resistance and immune suppression in cancer, a major challenge in oncology treatment today. The company's lead candidate, ENV105, targets CD105, a protein implicated in resistance to various cancer therapies. By focusing on CD105, ENV105 aims to reverse drug resistance, thereby enhancing the efficacy of standard treatments across multiple cancer types. Currently, ENV105 is undergoing Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer, addressing critical gaps in cancer treatment.
The implications of Kairos Pharma's research and development efforts are profound. Drug resistance remains a significant barrier to effective cancer treatment, often leading to disease relapse. The company's work could pave the way for more effective therapies, offering hope to patients with limited treatment options. The presentation at the H.C. Wainwright conference represents an opportunity for Kairos Pharma to engage with investors and the broader medical community, underscoring the potential of its technology to transform cancer care.
For those interested in learning more about Kairos Pharma's developments, additional information is available in the company's newsroom at https://ibn.fm/KAPA. This event marks a pivotal moment for Kairos Pharma as it seeks to advance its mission of delivering innovative solutions to some of the most challenging aspects of cancer treatment.
